Johnson & Johnson is engaged in the research, development, manufacture, and sale of a wide range of products in the healthcare field, including consumer staples, biotech, and medical technology sectors. In order to achieve a more focused organization, the company is considering a spin-off of the consumer section. While most peer group members in the medtech segment were hit by COVID procedure limitations, J&J grew that section by more than 16% in 2021. This occurred on the back of advancements in surgery using AI, amongst other breakthroughs.
The split of the 135-year-old J&J company will result in the separation of consumer brands like Band-Aid, Tylenol, Neutrogena, and Listerine from medical technology and pharmaceuticals. This will help keep the company at the forefront of surgical techniques that transform health care.
In 2021, in the middle of the pandemic, the company invested more than $2 billion in innovation. The ultimate aim is to combine science with ultra-high technology to deliver improved services and products to patients
On the medical side, the company has 14 new blockbusters in the launch pipeline. For all these products, GTM should occur prior to 2025.